Last updated on November 2019

An Investigational Immuno-therapy Study to Evaluate the Safety and Effectiveness of Experimental Medication BMS-986207 by Itself and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Broad Solid Tumor
  • Age: Between 18 - 100 Years
  • Gender: Male or Female

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit

Inclusion Criteria:

  • Women and men 18 years of age with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
  • Must have received and progressed on or failed one standard/approved treatment for cancer type, if available
  • At least 4 weeks since any previous treatment for cancer
  • Subject must consent to pretreatment and on treatment tumor biopsies
  • At least one lesion with measurable disease at baseline
  • Adequate organ and marrow function

Exclusion Criteria:

  • Patients with primary brain tumors or primary tumors with central nervous system metastases as only location of disease. Controlled brain metastases are permitted
  • Prior organ transplant
  • Participants with second/other active cancers requiring current treatment
  • Uncontrolled/significant heart disease
  • History of chronic hepatitis, Positive test for Hepatitis B virus surface antigen or Hepatitis C antibody (except participants with liver cancer) or Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome(HIV/AIDS)
  • Active/uncontrolled autoimmune disease
  • Active infection

Other protocol defined inclusion/exclusion criteria could apply

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.